CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Mehdi Hamadani, Medical College of Wisconsin, Milwaukee, US. We asked, CAR-T or stem cell transplant for second-line treatment of aggressive B-cell non-Hodgkin lymphoma (NHL)?

Hamadani begins by outlining the current treatment approaches, however, he explains the problems faced by high-risk patients and those who relapse early. He goes on to discuss three recent randomized studies investigating alternative treatments to improve outcomes for these patients (TRANSFORM, ZUMA, and BELINDA). Finally, Hamadani addresses how he would apply these findings to his own clinical practice, and makes some recommendations for certain treatment settings.